NEW YORK, May 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/exscientia-plc-loss-submission-form/?id=81713&from=4 ALLEGATIONS: The complaint alleges ...

Exscientia plc (NASDAQ:EXAI) Q1 2024 Earnings Conference Call May 21, 2024 8:30 AM ET Chinedu Okeke - Associate Director-Strategy, IR David Hallett - Interim CEO, Chief Scientific Officer Ben Taylor - CFO, Chief Strategy Officer Alec Stranahan - Bank of America Vikram Purohit - Morgan Stanley Peter Lawson - Barclays Hello, everyone. My name is Sarah, and I will be your conference operator today. At this time, I would like to welcome everyone to Exscientias' Business Update Call for the First Quarter 2024. A ...

Exscientia PLC Sponsored ADR (EXAI) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by ...

NEW YORK, May 22, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Exscientia p.l.c (NASDAQ: EXAI) between March 23, 2022 and February 12, 2024, both dates inclusive (the "Class Period"), of the important June 25, 2024 lead plaintiff deadline. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do ...

Morsa Images As Generative AI impacts drug research, this thesis aims to uncover the opportunities for Exscientia plc (NASDAQ:EXAI) and show it is a buy based on the strength of its technology platform. Noteworthily, I was again bullish when covering the stock in April 2022 priced at $12. It did rise to $15.21, but, subsequently, slid to $4.28 as the Federal Reserve hiked interest rates at such an aggressive pace only seen in the Paul Volcker Era. Trading at around $5 at the time of writing, the stock has u ...

NEW YORK, May 21, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Exscientia plc (NASDAQ: EXAI). Shareholders who purchased shares of EXAI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: DEADLINE: June 25, 2024 Shareholders should not delay in registering for this class action. Register your information here: https: ...

Core Viewpoint - Investors in Exscientia p.l.c. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred during the class period from March 23, 2022, to February 12, 2024 [1] Group 1: Allegations Against Defendants - The complaint alleges that Defendant Hopkins engaged in improper relationships with employees, violating the Company's standards and values [2] - Defendant Nicholson is accused of having prior knowledge of Hopkins's misconduct and addressing it inadequately without consulting the Board [2] - The Company is claimed to have inadequately maintained and enforced its Code of Business Conduct and Ethics, leading to increased risks of leadership transitions and reputational harm [2] - As a result of these failures, the positive statements made by Defendants regarding the Company's business and prospects were materially misleading [2] Group 2: Class Action Participation - Investors do not need to take any action at this time to be part of the class action and may choose to retain counsel or remain absent [3] - For further inquiries regarding the class action or individual rights, investors can contact the Law Offices of Howard G. Smith [3]

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Exscientia p.l.c. ("Exscientia" or the "Company") (NASDAQ: EXAI) and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 24-cv05692, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Exscientia securities between March 23, 2022, and Febraury 12, 202 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Exscientia p.l.c. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 25, 2024, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Exscientia securities between March 23, 2022, and February 12, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 25, 2024 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Exscientia's executives made false and misleading statements and failed to disclose improper relationships and inadequate enforcement of the company's Code of Business Conduct and Ethics [4]. - These failures allegedly exposed Exscientia to risks of leadership disruptions and reputational harm, leading to investor damages when the truth was revealed [4].

Question-and-Answer Session Operator [Operator Instructions] I will go to our first question from Alec Stranahan at Bank of America. Alec Stranahan Just a couple from us, actually, just on the automation capabilities that have come online. I'm trying to put maybe a better earmark around the dollar value that we could see this realized in the near term or medium term. I guess how do you see the facility playing out from a business perspective. Does that have a benefit to COGS or G&A and immediate impact? The ...